BioSpace News Archive

FDA Pulmonary, Allergy, and Rheumatology Division Veteran and Researcher Will Oversee the Company’s Medical and Regulatory Strategy

UroGen Pharma Ltd. announced that it will participate in fireside chats at the following conferences in November

New, first-to-market allograft solutions to be presented at the 2019 Desert Foot Conference

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present a company overview at the Stifel Healthcare Conference in New York City on Wednesday, November 20, 2019.

InVivo Therapeutics Holdings Corp. announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share.

RenovaCare, Inc., developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, announced the appointment of Alan L. Rubino as President and Chief Executive Officer.

Amyris, Inc. announced that it is moving into the regulatory stage with a new, undisclosed health and nutrition molecule.

Zymeworks Inc. announced the selection of an abstract highlighting updated single agent data from the Phase 1 clinical trial evaluating the HER2‑targeted bispecific antibody, ZW25, in patients with HER2‑expressing solid tumors for a mini oral presentation at the ESMO Asia 2019 Congress, taking place November 22 - 24 in Singapore.

Data from a new preclinical mouse study suggests a unique mechanism of CaPre compared to metformin and icosapent ethyl (VASCEPA®) in a diet-induced obesity animal model

In this study, researchers reported that administration of Tβ4 to animals with induced kidney injury significantly reduced ischemic acute kidney injury.